#AI Technology #Warsaw #Poland #Ingenix #Thalamus Reasoning

Ingenix’s Thalamus Reasoning Model Achieves Milestone in AI for Biology

In a remarkable achievement, Polish AI start-up Ingenix has announced that its innovative model, Thalamus Reasoning, has clinched the top position on LongevityBench, the reputable benchmark for assessing language models in cellular aging research. This model, an integral part of Ingenix's Biological Reasoning Engine, has not only set a new standard in performance but is also contributing to the open-source community by releasing a variant known as Thalamus Decision. This initiative aims to empower researchers across the globe to leverage the model in their work, promoting collaboration and further advancements in the field of AI-driven biology.

Benchmark Performance

The Thalamus Reasoning model is characterized by its impressive architecture, which incorporates a staggering 9 billion parameters. Ingenix's model outshone 28 other published models, including some of the most renowned systems developed by leading frontier labs. The results from the LongevityBench showcase Thalamus's exceptional capability to process complex data efficiently. With its transformative approach to biological data, Thalamus converts information related to DNA methylation, gene expression, and proteomics into simplified mathematical vectors—what Ingenix refers to as Modality Fusion. This technique enables the model to generate profiles using only four tokens, a stark contrast to the approximately 1.3 tokens needed by mainstream models like ChatGPT to process a single word, highlighting its efficiency.

Key Metrics Achieved

The Thalamus Reasoning model demonstrated stellar performance across various metrics. It secured the first position among 29 models on 14 ranked tasks within LongevityBench, achieving a mean rank of 1.42. This places it considerably ahead of the runner-up, which achieved a mean rank of 4.42. Remarkably, Thalamus also excelled in 11 of the 14 tasks, showcasing its versatility and robustness in handling different types of biological data. For instance, it recorded a DNA methylation age error of just 3.36 years, outperforming the best text-prompted model, which demonstrated an error of 12.9 years—this further underscores the precision and relevance of Thalamus in biological applications. Additionally, its accuracy in transcriptomics ordering at 0.828 marked a significant improvement over competing models.

Open Source Initiative

Ingenix’s commitment to open-source practices is a landmark step for the AI community. By releasing Thalamus Decision for public access, the company invites academic and commercial researchers to scrutinize and build upon Ingenix’s findings. This move is not merely strategic; it reflects a broader trend in the TechBio space, where innovation may arise from smaller, focused teams capable of integrating their knowledge of AI with biological expertise. CEO Piotr Surma emphasized, “Ranking ahead of frontier labs and specialized models on an independent benchmark validates our approach of Modality Fusion. It shows that when a reasoning model reads biological data as it was measured, rather than as text written about it, meaningful results can be delivered.”

Driving Change in Drug Discovery

The implications of Ingenix's work extend beyond benchmarks. Their innovative approach to AI in drug discovery underscores a paradigm shift. Rather than relying on larger systems attempting to address myriad problems simultaneously, Ingenix exemplifies how concentrated expertise in AI and biology can lead to significant advancements. Founded in 2023 and situated in Warsaw, this pioneering company brings together a team of leading minds in AI development, including those from the founding team of Applica, acquired by Snowflake in 2022. Their deep-rooted commitment to understanding biology through AI is positioning Ingenix at the forefront of medical and research advancements.

Conclusion

Ingenix’s trailblazing journey, marked by the Thalamus Reasoning model, signals exciting possibilities for AI in biological research. Their open-source initiatives not only foster innovation but also open doors for collaborative research efforts that can accelerate discoveries needed in the ever-evolving field of medicine. The future looks promising as Ingenix continues to push the boundaries of what AI can achieve in understanding complex biological processes, paving the road for groundbreaking advancements in health and medicine.